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The human polyomavirus JC (JCV) is the causative agent of the CNS demyelinating disease progressive
multifocal leukoencephalopathy (PML). Infection by JCV is extremely common and after primary
infection, JCV persists in a latent state. However, PML is a very rare disease suggesting that the virus is
tightly regulated. Previously, we showed that NF-kB and C/EBPb regulate the JCV early and late
promoters via a DNA control element, KB, which also mediates the stimulatory effects of proinﬂam-
matory cytokines such as TNF-a on JCV gene expression. Other studies have implicated NFAT4 in JCV
regulation. We now report that NFAT4 and NF-kB interact at the KB element to co-operatively activate
both JCV early and late transcription and viral DNA replication. This interplay is inhibited by C/EBPb
and by agents that block the calcineurin/NFAT signaling pathway. The importance of these events in the
regulation of JCV latency and reactivation is discussed.
& 2012 Elsevier Inc. All rights reserved.Introduction
The human neurotropic polyomavirus JC (JCV) is the causative
agent of a fatal central nervous system (CNS) demyelinating
disease known as progressive multifocal leukoencephalopathy
(PML) (Padgett et al., 1971). PML is caused by the reactivation
of latent infection of JCV in the CNS and is usually characterized
by multiple regions of demyelination, which are developed upon
lytic infection of oligodendrocytes, the myelin-producing cells of
the CNS, by JCV (Berger, 2007; Khalili et al., 2008). PML is a very
rare disease even though the proven etiological agent is very
common within the human population (White and Khalili, 2011).
Most people are infected with JCV in childhood and this initial
infection is not known to be related to any clinical disease.
Subsequently, JCV remains in a persistent but dormant state
known as latency, which is thought to be maintained due to the
action of the immune system. Thus, PML occurs almost exclu-
sively in individuals with impaired immune function. Once a very
rare disease, PML has gained attention due to the mounting body
of evidence showing reactivation of JCV in individuals with a
variety of immunodeﬁciency disorders. These include persons
with HIV-1/AIDS (Berger and Concha, 1995), patients with auto-
immune disorders receiving immunotherapeutic drugs, e.g., Natali-
zumab (Kleinschmidt-DeMasters and Tyler, 2005; Langer-Gould
et al., 2005; Van Assche et al., 2005; Khalili et al., 2007), Rituximabll rights reserved.
White).(Clifford et al., 2011), and Efalizumab (Kothary et al., 2011). PML can
also occur in transplant recipients receiving immunosuppressive
drugs to prevent rejection (Kumar, 2010; Mateen et al., 2011) and
individuals with lymphoproliferative and myeloproliferative disor-
ders (D’Souza et al., 2010) or who are chronically immunosup-
pressed due to a variety of other reasons (reviewed by Berger
(2007), Khalili et al. (2008)). Many important aspects of PML
pathogenesis remain unclear including the molecular basis and
tissue site(s) of viral latency and the reactivation mechanisms that
upregulate viral transcription and replication and induce PML
(reviewed in Berger, 2011; White and Khalili, 2011). A variety of
tissues have been reported to harbor latent JCV DNA including
kidney, tonsils, bone marrow and indeed the brain itself (Elsner and
Dorries, 1992; Greenlee et al., 2005; Mori et al., 1991, 1992; Perez-
Liz et al., 2008; Tan et al., 2010; White et al., 1992). The possibility
that JCV is present in the brain prior to onset of overt disease
suggests that the normal brain may be a site of viral latency and that
JCV reactivation events may occur in situ and involve CNS factors
such as cytokines that upregulate the expression of viral genes in
glial cells, though the importance of entry of JCV into the brain as
another barrier to PML should not be discounted (Berger, 2011).
The genome of JCV is a circular, closed, supercoiled DNA and is
small in size (5130 base pairs for the Mad-1 strain). It is
composed of two regions, early and late, which are transcribed
in opposite directions from a bidirectional promoter (Frisque
et al., 1984; Imperiale and Major, 2007). This bidirectional
promoter is also known as the noncoding control region (NCCR)
and governs viral early and late genes in opposite directions of the
circular polyomavirus DNA genome. The NCCR contains the
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expression. Signal transduction pathways that lie downstream of
extracellular growth factors and immunomodulators such as
proinﬂammatory cytokines, e.g., TNF-a, IL-1b, IL-6, regulate some
of these transcription factors. Our earlier work indicated the
involvement of the NF-kB signaling pathway in the activation of
JCV transcription (Mayreddy et al., 1996; Ranganathan and
Khalili, 1993; Romagnoli et al., 2009; Safak et al., 1999; Wollebo
et al., 2011). The unique site for NF-kB has been designated the
KB element and is located in the NCCR on the early side of the
origin of viral DNA replication. The KB element has shown to be a
functional NF-kB binding site by gel shift studies with the NF-kB
p65 subunit and activates JCV gene expression in response to PMA
(Ranganathan and Khalili, 1993). Our earlier observations on JCV
transcription indicate that the KB element is positively regulated
by NF-kB p65 binding and negatively regulated by isoforms of the
C/EBPb protein, which bind to an adjacent site within the KB
element (Romagnoli et al., 2009). In these experiments, a ternary
complex of NF-kB/p65, C/EBPb-LIP and JCV KB DNA could be
detected and mutagenesis analysis indicated that the KB element
regulates both basal and p65-stimulated transcription. We have
also found that TNF-a stimulated both early and late JCV tran-
scription through the KB element and that KB was able to confer
TNF-a responsiveness to a heterologous promoter (Wollebo et al.,
2011). Interestingly, Manley et al. (2006) reported that nuclear
factor of activated T cells 4 (NFAT4) has a role in JCV infection of
glial cells and suggested that it binds to the same region (KB
element).
NFAT transcription factors were ﬁrst described in lymphocytes
and remain one of the best-characterized targets for dephospho-
rylation by calcineurin (PP2B), a calcium/calmodulin-dependent
cell signaling phosphatase involved in T cell activation (Feske
et al., 2003). Many different roles for NFAT have now been
described in non-lymphoid tissue including neurons and glia
(Graef et al., 1999, 2001; Ho et al., 1994; Mosieniak et al., 1998;
Stevenson et al., 2001). There are currently ﬁve known members
of the NFAT family including NFAT1 (NFATp), NFAT2 (NFATc),
NFAT3 (NFATc4), NFAT4 (NFATc3/NFATx) and NFAT5 (Vihma
et al., 2008). NFAT4 is the only NFAT family member that is
expressed in the astroglial cells, U-87 MG and SVGA (Manley
et al., 2006). The ﬁrst four members of the NFAT family are
calcium regulated. The activity of the proteins is determined by
their phosphorylation state, which in turn is tightly regulated by
interplay between calcineurin and opposing kinases. Constitu-
tively-expressed NFAT proteins reside in the cytoplasm. When
calcineurin is activated through an increase in intracellular
calcium level, NFAT is dephosphorylated at a large number of
phosphorylated serine residues and rapidly enters the nucleus.
NFAT nuclear accumulation is rapid and reversible (Shibasaki
et al., 1996). Export occurs following rephosphorylation of NFAT
by kinases, including GSK-3, most likely by remasking the NLS
and allowing a constitutively active nuclear export signal to
dominate (Beals et al., 1997).
In the context of our earlier work on the control of JCV
transcription by the KB element, Manley et al (2006) reported
that the immunosuppressive drug cyclosporin A, which inhibits
calcineurin and activation of NFATS also inhibits JCV infection of
glial cells and that glial cells express only NFAT4, which was
found to bind to the JCV promoter in ChIP assays. Thus, it was of
interest to examine the interplay of NF-kB and NFAT4 at the KB
element of the JCV NCCR. We found that the transcription factors
NFAT4 and NF-kB p65 can each stimulate both early and late gene
expression activity through their binding to the KB element of the
JCV noncoding control region when expressed alone. When NFAT
and p65 are co-expressed, a co-operative stimulation of these
activities was observed.Results
NFAT4 and NF-kB p65 cooperate to stimulate JCV early and late
transcription via the KB element
In previous studies, we have identiﬁed an element (KB) in the JCV
noncoding control region that binds NF-kB p65 and mediates the
stimulation of JCV early and late transcription caused by NF-kB p65
expression and treatment of cells with PMA or TNF-a (Ranganathan
and Khalili, 1993; Mayreddy et al., 1996; Safak et al., 1999;
Romagnoli et al., 2009; Wollebo et al., 2011). Manley et al (2006)
reported that the transcription factor, NFAT4, which is the only
NFAT family member to be expressed in U-87 MG and SVGA cells,
may also act at this site to stimulate JCV transcription. Accordingly,
it was of interest to investigate the effects of NF-kB p65 and NFAT4,
each alone and in combination on early and late JCV transcription.
As shown in Fig. 1A, transient transfection of increasing amounts of
NFAT4 expression plasmid proportionately stimulated both early
and late transcription measured using luciferase reporter plasmids.
As we have reported before (Romagnoli et al., 2009), expression of
p65 also stimulated JCV early transcription (Fig. 1B, lanes 1–5).
When increasing amounts of p65 were expressed in the presence of
NFAT4, there was an additive enhancement of JCV early transcrip-
tion (Fig. 1B, lanes 6–8). An additive effect of p65 and NFAT4 was
also observed for JCV late transcription (Fig. 1B, lanes 9–12).
Recently, we described two KB element mutants (m1 and m2,
Romagnoli et al., 2009) that are defective in basal early transcription
and fail to respond to NF-kB p65 expression (Romagnoli et al., 2009)
or to the stimulation of cells with PMA or TNF-a (Wollebo et al.,
2011). These two mutants were cloned into a luciferase reporter
plasmid as described in Materials and Methods and tested for their
response to NFAT4 expression (Fig. 1C). The two mutants had lower
rates of basal transcription and did not respond to NFAT4 (Fig. 1C,
lanes 3–6) while the wild-type promoter had a slightly higher basal
rate of transcription (lane 7) and was inducible by NFAT4 (lane 8).
The activity of the basal wild-type JCV early luciferase reporter
promoter was signiﬁcantly higher than either m1 or m2 (marked
with an asterisk, lane 7) and was inducible more than three-fold by
NFAT4 (marked with a double asterisk, lane 8) and is in agreement
with the data in Fig. 1A. In a previous study (Wollebo et al., 2011),
we showed that the KB element was able to confer, upon a
heterologous constitutive promoter (Herpes simplex virus thymi-
dine kinase - tk), the ability to respond to TNF-a and the transient
transfection of expression plasmid for the transcription factor NF-kB
p65. NFAT4 is known to be activated by the calcium/calmodulin-
dependent phosphatase calcineurin (Clipstone and Crabtree, 1992).
As shown in Fig. 1D, tk reporter plasmid containing the JCV wild-
type KB element was activated by the calcium ionophore ionomycin
as well as by PMA (wt–tk, lanes 9–12). No activation was seen for
the native tk promoter (lanes 1–4) or with a promoter containing a
mutant KB element (mt–tk, lanes 5–8).
C/EBPb LIP isoform inhibits basal, NFAT4-stimulated and NFAT4/NF-kB
p65-stimulated transcription for both the JCV early and late promoters
In addition to the stimulatory effect of NF-kB p65 on the KB
element, we previously found that the transcription factor C/EBPb
binds to the same site and inhibits basal and NF-kB-stimulated JCV
transcription (Romagnoli et al., 2009). Of the three C/EBPb isoforms
(full-length, LIP and LAP), C/EBPb LIP was the strongest in this regard
and was shown to bind to the KB element by gel shift and ChIP
analyses and co-immunoprecipitation with antibody to NF-kB p65
(Romagnoli et al., 2009). Thus it was of interest to investigate the
effects of C/EBPb LIP and NFAT4, each alone and in combination on
JCV early and late transcription. As shown in Fig. 2A, C/EBPb LIP
inhibited basal and NFAT4-stimulated transcription of both the JCV
Fig. 1. Effect of ectopic expression of NFAT4 and NF-kB on JCV early and late promoter reporter expression. (A) U-87 MG cells were transfected with luciferase reporter
plasmid for the early promoter, JCVE-LUC (left), or late promoter, JCVL-LUC (center), in the presence or absence of increasing amounts of NFAT4 expression plasmid (0, 0.1,
0.2 and 0.8 mg). After 48 h, cells were harvested and assayed for luciferase activity. Activities were normalized to the activity for reporter alone. The error bars represent
standard deviation. Expression of NFAT4 was veriﬁed by Western blot using antibody against its C-terminal myc epitope tag as shown in the right-hand panel with a-
tubulin as a loading control. (B) U-87 MG cells were transfected JCVE-LUC (left) in the presence or absence of NFAT4 (0.3 mg) and/or increasing amounts of NF-kB p65
expression plasmid (0, 0.1, 0.3 and 0.5 mg). In the center panel, JCVL-LUC was used with NFAT4 and p65 alone or in combination. Expression of NFAT4 and p65 were
conﬁrmed by Western blot with a-tubulin as a loading control (right-hand panel). (C) U-87 MG cells were transfected with JCVE-LUC reporter plasmid containing either
plasmid vector negative control (NEG CON), the m1 or m2 KB element mutation or with wild-type (wt) promoter in the presence or absence of NFAT4 (0.9 mg). After 48 h,
cells were harvested and assayed for luciferase activity. Luciferase activity was normalized to wild-type JCVE-LUC reporter activity in the absence of NFAT4 (lane 7).
Western blot is shown inset. (D) U-87 MG cells were transfected with a CAT reporter plasmid pBLCAT2 containing the constitutive Herpes simplex virus thymidine kinase
(tk) promoter driving CAT expression or heterologous promoter containing tandem JCV kB elements, either mutant (mt–tk) or wild-type (wt–tk). Cells were treated with
ionomycin and/or PMA as described in Materials and Methods and assayed for CAT activity.
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and p65 were coexpressed, their cooperative effects on both early
and late transcription (lanes 3 and 7, respectively) were strongly
inhibited by C/EBPb LIP (lanes 4 and 8). Thus C/EBPb LIP inhibits
basal, NFAT4-stimulated and NFAT4/p65-stimulated JCV early and
late transcription.Cyclosporine and VIVIT inhibit JCV replication
The immunosuppressive drug cyclosporine A is an inhibitor of
the calcium-calmodulin-dependent protein serine phosphatase cal-
cineurin also known as protein phosphatase-2B (PP2B, Clipstone and
Crabtree, 1992), which dephosphorylates and thereby activates
Fig. 2. Effect of ectopic expression of NFAT4 and C/EBPb on JCV early and late promoter reporter expression. (A) U-87 MG cells were transfected with JCVE-LUC (left) or
JCVL-LUC, in the presence or absence of NFAT4 (0.5 mg) and/or C/EBPb LIP (0.5 mg) expression plasmid (center). After 48 h, cells were harvested and assayed for luciferase
activity. Activities were normalized to the activity for reporter alone. The error bars represent standard deviation. Expression of NFAT4 and LIP was conﬁrmed by Western
blot with a-tubulin as a loading control (right). (B) As for A except also including NF-kB p65 expression plasmid.
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ine reduces the efﬁciency of JCV infection consistent with a role for
NFATs in the JCV life cycle. Accordingly, we transfected/infected
SVGA cells with JCV in the presence and absence of cyclosporine and
measured viral DNA replication using the DpnI assay (Fig. 3), which
distinguished input DNA from DNA that has been replicated. As
shown in Fig. 3A, a band of replicated DNA corresponding in size to
the plasmid restriction fragment of JCV genomic DNA (lane 1) was
observed in the infected cells, untreated and cyclosporine-treated
(lanes 3 and 4, respectively). Comparison of the intensities of the
bands measured using Bio-Rad QuantityOne software indicated that
cyclosporine caused an 80% inhibition of JCV DNA replication. From
the same infection experiment, we also harvested protein samples
and performed Western blots for the JCV late proteins VP1 and
agnoprotein (Fig. 3B). Cyclosporine caused a 50% and 40% reduction
in the level of VP1 and agnoprotein expression, respectively (com-
pare lanes 3 and 4).
In order to identify more potent and selective inhibitors of
NFAT activation than cyclosporine, Aramburu et al (1999)
employed an afﬁnity-driven peptide selection approach to select
a high-afﬁnity calcineurin-binding peptide from combinatorial
peptide libraries based on the calcineurin docking motif of NFAT.
An optimal peptide MAGPHPVIVITGPHEE (referred to as VIVIT)
was identiﬁed which, when expressed as a fusion protein with
green ﬂuorescent protein (GFP), efﬁciently inhibited calcineurin-
dependent nuclear translocation of NFAT (Aramburu et al., 1999).
Next, we used VIVIT to further investigate a role for NFAT in viral
replication using DpnI assay and Southern blot as described
above. Accordingly, we transfected/infected SVGA cells with JCV
in the presence and absence of co-transfection of GFP-VIVIT or
GFP expression plasmids and measured viral DNA replication
using the DpnI assay (Fig. 3C). As shown in Fig. 3A, a band of
replicated DNA corresponding in size to the plasmid restriction
fragment of JCV genomic DNA (lane 1) was observed in theinfected cells, GFP and GFP-VIVIT-transfected (lanes 4 and
5 respectively). Comparison of the intensities of the bands
measured using Bio-Rad QuantityOne software indicated that
VIVIT caused a 60% inhibition of JCV DNA replication. Similarly,
in the same infection experiment, Western blots for the JCV VP1
and agnoprotein showed that VIVIT caused a 60% and 80%
reduction in the levels of VP1 and agnoprotein expression,
respectively (Fig. 3D). All experiments were repeated twice and
the differences were signiﬁcant.
JCV early and late transcription are strongly inhibited by VIVIT and
siRNAs to PP2BAa and PP2BAb
To test the effect of VIVIT inhibition of NFAT on JCV early
transcription, we transfected U-87 MG cells with JCV early
reporter plasmid and various combinations of expression plas-
mids for NFAT4, p65 and GFP-VIVIT (Fig. 4A). VIVIT strongly
inhibited basal and NFAT4-stimulated early promoter activity
(compare lane 1–lane 3 and lane 2–lane 4). Interestingly, VIVIT
also inhibited p65-stimulated early promoter activity (compare
lane 5–lane 6). If GFP replaced GFP-VIVIT, no effect on transcrip-
tion was observed (data not shown). When the experiment was
performed with the JCV late promoter, similar results were
obtained (Fig. 4B). In the next series of experiment, we examined
the effect of VIVIT in the presence of JCV T-antigen on JCV early
(Fig. 4C) and late transcription (Fig. 4D). In both cases, VIVIT
strongly inhibited transcription. Remarkably, the late promoter
was stimulated over 30-fold by T-antigen (Fig. 4D, compare lanes
1 and 5) but this was reduced to only two-fold in the presence of
VIVIT (lane 6).
In another approach to investigate the role of calcineurin/NFAT
signaling in JCV transcriptional control, we employed RNA inter-
ference. The catalytic subunit of calcineurin (PP2BA) has three
isoforms (a, b and g), with PP2BAa and PP2BAb having a ubiquitous
Fig. 3. Effect of cyclosporine and VIVIT on JCV replication. (A) SVGA cells were transfected/infected with JCV Mad-1 genomic DNA in the absence ( CYCLO) or presence (þ
CYCLO) as described in Materials and Methods. After 10 days, DNA was harvested and subject to DpnI assay for replicated viral DNA. Positive control—inearized JCV
genomic DNA; Negative control—uninfected SVGA cell extract. The arrowhead indicates the position of replicated viral DNA. (B) Proteins harvested from the same cultures
as Panel A were assayed by Western blot for the expression of VP1 and agnoprotein. Alpha-tubulin was used as a loading control. C. SVGA cells were transfected/infected
with JCV Mad-1 genomic DNA together with plasmid expressing GFP (–VIVIT) or GFP-VIVIT (þ VIVIT) as described in Materials and Methods. After 10 days, DNA was
harvested and subject to DpnI assay for replicated viral DNA. Positive control—linearized JCV genomic DNA; Negative control—uninfected SVGA cell extract. Lane 3 was
not loaded. The arrowhead indicates the position of replicated viral DNA. (D) Proteins harvested from the same cultures as Panel A were assayed by Western blot for the
expression of VP1 and agnoprotein. Alpha-tubulin was used as a loading control.
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(Shibasaki et al., 2002). The relative functional roles of PP2BAa and
PP2BAb in a given signaling process can be assessed by using siRNAs
speciﬁc to each one (Seiferth et al., 2012). Accordingly, we examined
the effects of siRNA to PP2BAa (Fig. 4E) and PP2BAb (Fig. 4F) on JCV
early and late transcription. In the presence of siRNA to PP2BAa, the
early promoter was inhibited about 10-fold (Fig. 4E, left panel,
compare lanes 1 and 3) and NFAT4-stimulated expression was
inhibited about 5-fold (compare lanes 2 and 4). Control non-
targeting siRNA had no signiﬁcant effect (compare lane 1–5 and
lane 2–6). A similar effect of siRNA to PP2BAawas seen with the late
promoter (Fig. 4E, right panel). In the presence of siRNA to PP2BAb,
there was also a similar pattern of inhibition of transcription but
slightly less pronounced. For example, the early promoter was
inhibited about 2-fold (Fig. 4F, left panel, compare lanes 1 and 3).
These data indicate that both the PP2Ba and PP2Bb isoforms of
calcineurin are involved in signal transduction to the JCV promoters.
Both NFAT4 and p65 bind to KB element DNA in gel shift assays
Our previous work had characterized the binding of NF-kB p65
and C/EBPb LIP to the KB element of the JCV NCCR using gel shift
assays (Romagnoli et al., 2009). To characterize NFAT4 binding, we
performed a series of gel shift experiments with the KB element
probe and nuclear extracts from cells expressing combinations of
NFAT4, p65 and C/EBPb LIP (Fig. 5A). Since, we were unable to
produce a supershift after trying several different antibodies to
NFAT4, we included a series of gel shifts in the presence of siRNAs to
PP2BAa and PP2BAb to knock out calcineurin activity and hence
allow the identiﬁcation of the NFAT4 gel shift band (Fig. 5A, lower
panel). In the presence of non-targeting siRNA, the upper band shift(band position 3) was intensiﬁed when NFAT4 was expressed alone
(lane 3), compared to the control (lane 2). Co-expression of NFAT4
and p65 (lane 4), produced new band shifts (band position 2 and 4).
Further, these bands were eliminated in the presence of siRNAs to
PP2BAa and PP2BAb (lane 14) indicating that NFAT4 is present in
these complexes. In contrast, gel shift bands induced by co-expres-
sion of p65 and LIP (lane 6) were unaffected by the presence of
siRNAs to PP2BAa and PP2BAb (lane 16). Binding of p65 was
conﬁrmed by supershift (band position 1) with antibody to p65
(lane 10). Cold competitor KB element DNA eliminated all the bands
(lanes 8 and 18). Expression of NFAT4, p65 and LIP and knockdown
of PP2BAa and PP2BAb were veriﬁed by Western blot (Fig. 5B).Discussion
Our data indicate that the transcription factors NFAT4 and NF-
kB p65 stimulate both early and late gene expression activity
through their binding to the KB element of the JCV noncoding
control region. When NFAT and p65 are co-expressed, a co-
operative stimulation of these activities was observed. C/EBPb,
which can bind to the KB element in complex with NF-kB to inhibit
early and late transcription (Romagnoli et al., 2009), also inhibited
the transcription stimulation of NFAT4 and combined NFAT4/NF-
kB. Similarly, the calcineurin/NFAT inhibitor VIVIT inhibits not only
early and late transcription stimulated by NFAT4 but also by p65.
These data suggest a co-operative interplay between NFAT4 and
NF-kB. Binding of NFAT4 to the KB element of the JCV NCCR was
supported by gel shift experiments using RNA interference with
siRNAs to calcineurin to knock out NFAT4 binding. Thus NFAT4 and
NF-kB, the effectors of two different signal transduction pathways
Fig. 4. Effect of ectopic expression of VIVIT on NFAT4 and NF-kB stimulation of JCV early and late promoter reporter expression. (A) U-87 MG cells were transfected with
luciferase reporter plasmid for the early promoter, JCVE-LUC in the presence or absence of amounts of NFAT4, NF-kB p65 and/or GFP-VIVIT expression plasmids. After 48 h,
cells were harvested and assayed for luciferase activity. Activities were normalized to the activity for reporter alone. The error bars represent standard deviation. When
GFP expression plasmid was used in place of GFP-VIVIT, there was no effect (data not shown). (B) As for A, except with JCVL-LUC as the reporter plasmid. (C) U-87 MG cells
were transfected with JCVE-CAT reporter plasmid in the presence or absence of amounts of NFAT4, JCV large T-antigen (T-Ag) and/or GFP-VIVIT expression plasmids. (D) As
for C, except with JCVL-LUC as the reporter plasmid. (E) U-87 MG cells were untreated or treated with siRNA to PP2BAa (asiRNA) or non-targeting siRNA (NT-siRNA) and
then transfected with JCVE-LUC or JCVL-LUC in the presence or absence of NFAT4 expression plasmid as indicated. Activities were normalized to the activity for reporter
alone. The error bars represent standard deviation. (F) As for E, except with siRNA to PP2BAb (bsiRNA).
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point on the JCV KB control element, which may be an important
regulatory event for the status of viral activation. There are other
reports of cooperative regulation by NFAT and NF-kB, e.g., the NF-
kB site in intron 1 of the ICAM-1 gene (Xue et al., 2009) and the C3-
3P NF-kB site of the IFN-g promoter (Sica et al., 1997).What is the importance of this interaction in viral regulation?
The JCV life cycle is marked by latency, where neither transcription
nor replication occurs, and then reactivation leading to host cell lysis
and PML. Latent JCV DNA has been detected in a variety of different
tissues (reviewed in Berger, 2011; White and Khalili, 2011) includ-
ing the brain (Elsner and Dorries, 1992; Greenlee et al., 2005; Mori
Fig. 5. Gel shift analysis of transcription factor binding to the JCV KB element. (A)
U-87 MG cells were transfected with expression plasmids for NFAT4, NF-kB p65
and/or C/EBPb LIP in various combinations as indicated in the presence of either
non-targeting siRNA (NT-siRNA, upper panel) or a mixture of siRNAs to PP2BAa
and PP2BAb (a/b-siRNA, lower panel). Nuclear extracts were prepared and
incubated with radiolabeled probe corresponding to the JCV KB site as described
in Materials and Methods. n—probe alone; a-p65—antibody to p65 was included;
NRS—nonimmune rabbit serum was included; COMP—unlabeled KB element
competitor DNA was included. (B) Western blot analysis of all of the nuclear
extracts used in Panel A was performed for NFAT4, p65 and LIP with Lamin A/C as
a loading control. For the upper four panels (proteins expressed from transfected
plamids), the data for the extracts with a/b-siRNA are shown and essentially the
same results were obtained for the extracts with NT-siRNA (data not shown). For
the lower panels (illustrating RNA interference for PP2BAa and PP2BAb), the
extracts with a/b-siRNA are shown immediately below the extracts with NT-
siRNA for each Western. Note that the extracts were run on parallel gels, transfers
and exposed to the same X-ray ﬁlm, which was processed in the same image ﬁle
so as to accurately reﬂect changes in PP2BAa and PP2BAb protein levels between
a/b–NT and a/b-siRNA in all lanes and included lamin A/C as loading control.
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1992). Of note, the virus found in brain has a rearranged NCCR
region that is characteristic of pathogenic forms of the virus, also
known as ‘‘PML-type’’ and not the archetypal form of the virus that
is found in the kidney (Perez-Liz et al., 2008; Tan et al., 2010; White
et al., 1992). The rearrangements in the late-proximal region of theJCV NCCR are undoubtedly important in pathogenesis since they
allow the duplication of important promoter/enhancer elements, as
typiﬁed by the 98 base-pair repeat of the Mad-1 strain, and also the
deletion of archetypal elements that may restrict promoter activity
(Daniel et al., 1996). However, the ﬁnding of latent PML-type viral
DNA in normal brain implies that mechanisms must exist for
switching the JCV NCCR ‘‘on and off’’. We hypothesize that the KB
element may provide the basis for such a switching mechanism.
The KB element, found in the highly conserved early proximal
portion of the JCV NCCR, binds and is activated by NF-kB and TNF-a
(Ranganathan and Khalili, 1993; Mayreddy et al., 1996; Safak et al.,
1999; Romagnoli et al., 2009; Wollebo et al., 2011). In another study,
Manley et al (2006) reported that NFAT4 was required for JC virus
infection. We now conﬁrm and extend these observations by show-
ing that NF-kB and NFAT4 co-operatively activate the transcriptional
status of JCV through the KB element. Most cases of PML occur in
HIV-1/AIDS where HIV-1 can generate cytokine cascades in the CNS
including TNF-a (Benveniste, 1994; Kaul et al., 2005; Wesselingh
et al., 1993; Yeung et al., 1995). TNF-a stimulates JCV transcription
(Wollebo et al., 2011), and hence co-operative interaction between
NF-kB and NFAT pathways downstream of TNF-a (Yarilina et al.,
2008) and converging at the KB element may be involved in JCV
reactivation and PML. Of note, robust levels of TNF-a and TNFR1 are
found in HIV/PML clinical samples (Wollebo et al., 2011).
It is also possible in HIV/PML that HIV itself might impart a
direct effect on the JCV KB element through the action of the HIV
transactivator protein Tat, which also activates JCV (Tada et al.,
1990). HIV Tat increases the activity of NF-kB (Mahlknecht et al.,
2008; Taylor et al., 1992) and the NFAT pathway (Lo´pez-Huertas
et al., 2010; Pessler and Cron, 2004; Vacca et al., 1994). It should
be noted that HIV-1 provirus itself is regulated by NF-kB, NFAT
and Tat and that these signaling proteins are thought to be
involved in the activation of latent HIV-1 transcription when
resting T-cells become activated (Coiras et al., 2009; Kinoshita
et al., 1997; Pessler and Cron, 2004).
In summary, these studies suggest that the inactive latent JC
virus that has been detected in the normal brain of some
individuals may be subject to a switching mechanism via the KB
element whereby cooperative actions of NF-kB and NFAT signal-
ing which may promote JCV reactivation downstream of cyto-
kines such as TNF-a. Such events in the context of impaired
immunosurveillance may initiate viral replication and the forma-
tion of PML lesions. A deeper understanding of these processes
may suggest new ways to prevent and treat PML.
Conclusions
Two transcription factors, NF-kB p65 and NFAT4, which lie
downstream of different signal transduction pathways have the
capacity to bind to a common element (KB) in the JCV noncoding
control region and thereby cooperatively activate both early and
late transcription. Inhibition of either NFAT4 by calcineurin
inhibitors such as cyclosporine or VIVIT or NF-kB, by C/EBPb
LIP, prevents this activation. This novel mechanism may be
involved in the reactivation of JCV from latency in glial cells in
response to extracellular cytokines.Materials and methods
Cell culture and plasmids
U-87 MG human glioblastoma and SVGA were maintained in
Dulbecco’s Modiﬁed Eagle’s Medium (DMEM) supplemented with
10% fetal bovine serum (FBS). Reporter constructs, JCVE-LUC and
JCVL-LUC contained the JCV promoter from the Mad-1 strain
H.S. Wollebo et al. / Virology 432 (2012) 146–154 153linked to the luciferase gene in the early and late orientations,
respectively (Wollebo et al., 2011). JCVE-LUC promoter mutants
m1 and m2 containing mutations at two adjacent sites within the
KB site (Romagnoli et al., 2009) were made by excising the JCV
Mad-1 NCCR from JCVE-CAT promoter mutants m1 and m2
(Romagnoli et al., 2009) and cloning them into the BglII site of
pGL3-basic (Promega). Heterologous reporter plasmids, pBLCAT2-
wt-kB and pBLCAT2-mt-kB were described previously and were
made by cloning tandem wild-type or mutant JCV kB sites
respectively into the CAT reporter plasmid pBLCAT2, which
contains the constitutive Herpes simplex virus thymidine kinase
(tk) promoter (Wollebo et al., 2011). The expression plasmids
pCMV-p65 and pCMV-LIP were described previously (Romagnoli
et al., 2009). The pGFP-VIVIT construct expresses the NFAT
peptide inhibitor VIVIT fused with green ﬂuorescent protein
(GFP) under the control of the cytomegalovirus (CMV) promoter
(Addgene, Cambridge MA). Plasmid containing the full-length
human cDNA of NFAT4 was purchased from Open Biosystems
(Huntsville, AL). The full length NFAT4 was PCR ampliﬁed from
the plasmid pOTB7 and cloned in EcoR1 and Xho1 site of the
pCDNA6A expression vector using the following primers. The
forward primer was 50- ctg gtt gaa ttc gcc acc atg act act gca aac
tgt ggc-30 and the reverse primer was 50- cta aca ctc gag gag ccc
atc aga tct tcc taa atc-30.
Antibodies
Rabbit polyclonal anti-p65 (c-20, sc-372, Santa Cruz Biotech-
nology Inc., Santa Cruz, CA) and mouse monoclonal anti-C/EBPb
(H7, sc-7962, Santa Cruz) which recognizes all three C/EBPb
isoforms were used for Western blots. Mouse monoclonal anti-
a-tubulin (clone B512) was from Sigma (St. Louis, MO) and mouse
monoclonal anti-myc-Tag antibody (9B11) and rabbit polyclonal
antibody to lamin A/C were from Cell Signaling Technologies, Inc.
(Danvers MA). Goat polyclonal antibodies to PP2B-Aa (C-20) and
PP2B-Ab (C-20) were from Santa Cruz. Mouse monoclonal anti-
body (Ab587) against JCV capsid protein VP1 was kindly provided
by Dr. Walter Atwood, Brown University, Providence RI. Rabbit
polyclonal antibody against JCV agnoprotein was previously
described (Del Valle et al., 2002).
Western blots
Western blot assays were performed as previously described
(White et al., 2006). Brieﬂy, 50 mg of protein was resolved by SDS-
PAGE, transferred to nitrocellulose, and immunoblotted with
primary antibody (1/1000 dilution) and secondary antibody
(1/10000 dilution). Bound antibody was detected with an ECL
detection kit (Amersham, Arlington Heights, IL).
Transient transfection assays
Experiments involving co-transfection of reporter plasmids
and expression plasmids were performed as we have previously
described (Romagnoli et al., 2009; Wollebo et al., 2011). Brieﬂy,
U-87 MG cells were transfected with reporter constructs alone
(5 mg) or in combination with the various expression plasmids.
The total amount of transfected DNA was normalized with empty
vector DNA. When PMA and ionomycin were used, 100 ng/ml
PMA and 2 mM ionomycin were added to the cultures 90 min
before harvesting. Assays for luciferase and CAT were performed
as previously described (Romagnoli et al., 2009; Wollebo et al.,
2011). For RNA interference experiments, 200 nmol of Smartpool
siRNA (Dharmacon, Lafayette, CO) was transfected against
PP2BAa, PP2BAb or non-targeting (NT) into cells 48 h prior to
transfection with the reporter plasmid.Gel shift assays
U-87 MG cells were transfected with a mixture of siRNA
against PP2BAa and PP2BAb (200 nmol) or non-targeting siRNA
(200 nmol) followed 48 h later by a second transfection with
expression plasmids for 36 h and then harvested. Nuclear proteins
were then extracted and 10 mg were incubated with 50,000 cpm
of a g-32P-labeled double-stranded oligodeoxyribonucleotide
probe as previously described (Romagnoli et al., 2009). The probe
that was used in these gel shift experiments corresponded to the
KB element: kB: 50-aaaacaagggaatttccctggcctc-30 (nts 5052-5078,
JCV Mad-1 reference strain, GenBANK # NC_001699).
Transfection/infection
SVGA cells, which express SV40 T-antigen and support JCV
replication were seeded at 1.5106 cells/75 cm2 ﬂask and trans-
fected with wild-type Mad-1 genomic DNA using 7 mg with
FuGene6 transfection reagent according to Manufacturer’s recom-
mendations (Roche, Indianapolis, IN). In experiments to test the
effect of VIVIT, cells were transfected with either 7 mg pGFP-VIVIT
or pGFP (control) 24 h before the viral DNA transfection. In
experiments to test the effect of cyclosporine A, cells were treated
6 h before transfection/infection with cyclosporine A (10 mM ﬁnal
concentration). Cells were then maintained at 37oC in a humidi-
ﬁed atmosphere with 7% CO2 for 10 days with every 3 days the
medium changed for fresh medium with cyclosporine A until they
were processed for protein extraction or DNA isolation. Protein
extracts were analyzed by Western blot for VP1 and agnoprotein
expression. After transfection/infection, cells were harvested and
low molecular weight DNA containing JC viral DNA was isolated
using Qiagen spin columns as described by Ziegler et al. (2004).
The JCV viral DNA was then digested with BamHI and DpnI
restriction enzymes, resolved on 1% agarose gel and analyzed by
Southern blotting using probe prepared from whole Mad-1
genome. DpnI is a methylation-sensitive of adenine residue
enzyme that requires methylation of adenine, which only occurs
in bacteria, and hence it digests transfected input DNA since but
DNA that has been replicated. The intensity of the 5.13 Kb BamHI
band in Southern blot is thus a measure of DNA replication.Acknowledgments
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